Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania....
+See More2019-11-07 14:36:00 Thursday ET
America expects to impose punitive tariffs on $7.5 billion European exports due to the recent WTO rule violation of illegal plane subsidies. World Trade Org
2018-08-27 09:35:00 Monday ET
President Trump and his Republican senators and supporters praise the recent economic revival of most American counties. The Economist highlights a trifecta
2018-05-09 08:31:00 Wednesday ET
CBS and its special committee of independent directors have decided to sue the Redstone controlling shareholders because these directors might have breached
2023-12-09 08:28:00 Saturday ET
International trade, immigration, and elite-mass conflict The elite model portrays public policy as a reflection of the interests and values of elites. I
2019-05-11 10:28:00 Saturday ET
The Trump administration still expects to reach a Sino-U.S. trade agreement with a better mechanism for intellectual property protection and enforcement. Pr
2020-04-17 07:23:00 Friday ET
Clayton Christensen defines and delves into the core dilemma of corporate innovation with sustainable and disruptive advances. Clayton Christensen (2000)